Drug Interactions between brigatinib and Lamprene
This report displays the potential drug interactions for the following 2 drugs:
- brigatinib
- Lamprene (clofazimine)
Interactions between your drugs
clofazimine brigatinib
Applies to: Lamprene (clofazimine) and brigatinib
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme. When a single 90 mg dose of brigatinib was administered with the potent CYP450 3A4 inhibitor itraconazole (200 mg twice daily), brigatinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 21% and 101%, respectively, compared to brigatinib administered alone. Simulations from a physiologically-based pharmacokinetic model predict a moderate CYP450 3A4 inhibitor may increase the AUC of brigatinib by approximately 40%.
MANAGEMENT: Concomitant use of moderate CYP450 3A4 inhibitors should generally be avoided during therapy with brigatinib. If coadministration is required, the brigatinib dose should be reduced by approximately 40% (i.e., from 180 mg to 120 mg, 120 mg to 90 mg, or from 90 mg to 60 mg). Some authorities state that no dose adjustment is required. However, patients should be monitored for increased brigatinib adverse reactions such as nausea, vomiting, diarrhea, hypertension, bradycardia, hyperglycemia, visual disturbances, lymphopenia, anemia, and elevations in pancreatic enzymes and creatine phosphokinase. If a dose adjustment is made, the brigatinib dose that was tolerated previously may be resumed following discontinuation of the CYP450 3A4 inhibitor.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2017) "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc
Drug and food interactions
brigatinib food
Applies to: brigatinib
Grapefruit juice can increase the blood levels of brigatinib. This may increase side effects such as nausea, vomiting, diarrhea, high blood pressure, high blood sugar, slow heart rate, visual disturbances, anemia, and infections. You should avoid consuming grapefruit and grapefruit juice during treatment with brigatinib. Seek medical attention if you develop paleness, fatigue, dizziness, fainting, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain and burning during urination. Talk to your healthcare provider if you have any questions or concerns.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.